Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$12.55
0.000.00%
Pre-Market: 4:24 PM EDT
Comments
Loading...
Nurix Therapeutics Analyst Ratings and Price Targets | NASDAQ:NRIX | Benzinga
Nurix Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Nurix Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Morgan Stanley
RBC Capital
JP Morgan
Stifel
1calculated from analyst ratings
Analyst Ratings for Nurix Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/17/2025 | Buy Now | — | Leerink Partners | Faisal Khurshid29% | → $16 | Initiates | → Market Perform | Get Alert |
| 02/03/2025 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $16 → $17 | Maintains | Equal-Weight | Get Alert |
| 01/29/2025 | Buy Now | — | RBC Capital | Gregory Renza48% | $26 → $27 | Maintains | Outperform | Get Alert |
| 01/29/2025 | Buy Now | — | JP Morgan | Eric Joseph47% | $31 → $30 | Maintains | Overweight | Get Alert |
| 01/29/2025 | Buy Now | — | Stifel | Stephen Willey52% | $34 → $36 | Maintains | Buy | Get Alert |
| 01/29/2025 | Buy Now | — | Needham | Gil Blum51% | $29 → $28 | Maintains | Buy | Get Alert |
| 01/29/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $35 → $36 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | — | Stephens & Co. | Sudan Loganathan31% | $31 → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $30 → $35 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | — | BTIG | Jeet Mukherjee 7% | → $35 | Initiates | → Buy | Get Alert |
| 12/10/2024 | Buy Now | — | Needham | Gil Blum51% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2024 | Buy Now | — | BMO Capital | Etzer Darout48% | → $35 | Initiates | → Outperform | Get Alert |
| 11/06/2024 | Buy Now | — | Needham | Gil Blum51% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | — | UBS | David Dai26% | → $35 | Initiates | → Buy | Get Alert |
| 10/21/2024 | Buy Now | — | Needham | Gil Blum51% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $26 → $30 | Maintains | Buy | Get Alert |
| 10/14/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $27 → $26 | Maintains | Outperform | Get Alert |
| 10/14/2024 | Buy Now | — | Stephens & Co. | Sudan Loganathan31% | $31 → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 10/14/2024 | Buy Now | — | Needham | Gil Blum51% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Jefferies | Roger Song33% | → $41 | Initiates | → Buy | Get Alert |
| 09/04/2024 | Buy Now | — | Oppenheimer | Mark Breidenbach46% | $27 → $30 | Maintains | Outperform | Get Alert |
| 08/14/2024 | Buy Now | — | Oppenheimer | Mark Breidenbach46% | $25 → $27 | Maintains | Outperform | Get Alert |
| 07/31/2024 | Buy Now | — | Truist Securities | Srikripa Devarakonda48% | → $36 | Initiates | → Buy | Get Alert |
| 07/15/2024 | Buy Now | — | JP Morgan | Eric Joseph47% | $31 → $34 | Maintains | Overweight | Get Alert |
| 07/15/2024 | Buy Now | — | Barclays | Peter Lawson42% | $20 → $31 | Maintains | Overweight | Get Alert |
| 07/12/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $26 → $27 | Maintains | Outperform | Get Alert |
| 07/12/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $29 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $23 → $26 | Maintains | Outperform | Get Alert |
| 06/18/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $19 → $26 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | — | JP Morgan | Eric Joseph47% | $30 → $31 | Maintains | Overweight | Get Alert |
| 06/17/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | — | Piper Sandler | Joseph Catanzaro42% | $35 → $35 | Maintains | Overweight | Get Alert |
| 05/15/2024 | Buy Now | — | Stifel | Stephen Willey52% | → $27 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | — | Stephens & Co. | Sudan Loganathan31% | → $20 | Initiates | → Overweight | Get Alert |
| 04/11/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $22 → $23 | Maintains | Outperform | Get Alert |
| 04/11/2024 | Buy Now | — | Baird | Joel Beatty69% | $24 → $25 | Maintains | Outperform | Get Alert |
| 04/10/2024 | Buy Now | — | Needham | Gil Blum51% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $9 → $10 | Maintains | Equal-Weight | Get Alert |
| 02/20/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $35 → $19 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | — | Wells Fargo | Derek Archila58% | $23 → $20 | Maintains | Overweight | Get Alert |
| 02/16/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $24 → $22 | Maintains | Outperform | Get Alert |
| 02/02/2024 | Buy Now | — | Needham | Gil Blum51% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 11/02/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | $29 → $24 | Maintains | Outperform | Get Alert |
| 10/13/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | $30 → $29 | Maintains | Outperform | Get Alert |
| 10/13/2023 | Buy Now | — | Needham | Gil Blum51% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $33 → $35 | Maintains | Buy | Get Alert |
| 09/07/2023 | Buy Now | — | Needham | Gil Blum51% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $53 → $33 | Maintains | Buy | Get Alert |
| 07/17/2023 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $11 → $12 | Maintains | Equal-Weight | Get Alert |
| 06/26/2023 | Buy Now | — | Oppenheimer | Mark Breidenbach46% | → $25 | Assumes | → Outperform | Get Alert |
| 04/27/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | → $53 | Reiterates | → Buy | Get Alert |
| 04/21/2023 | Buy Now | — | Needham | Gil Blum51% | → $31 | Reiterates | → Buy | Get Alert |
| 04/14/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $30 | Reiterates | → Outperform | Get Alert |
| 04/14/2023 | Buy Now | — | Needham | Gil Blum51% | → $31 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | → $53 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | — | Barclays | Peter Lawson42% | → $20 | Initiates | → Overweight | Get Alert |
| 02/28/2023 | Buy Now | — | Oppenheimer | Mark Breidenbach46% | → $25 | Initiates | → Outperform | Get Alert |
| 02/14/2023 | Buy Now | — | Stifel | Stephen Willey52% | $37 → $31 | Maintains | Buy | Get Alert |
| 02/13/2023 | Buy Now | — | JP Morgan | Eric Joseph47% | $37 → $36 | Maintains | Overweight | Get Alert |
| 02/10/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | → $53 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | $39 → $30 | Maintains | Outperform | Get Alert |
| 02/10/2023 | Buy Now | — | Needham | Gil Blum51% | $32 → $31 | Maintains | Buy | Get Alert |
| 12/13/2022 | Buy Now | — | SVB Leerink | Andrew Berens48% | $37 → $28 | Maintains | Outperform | Get Alert |
| 10/11/2022 | Buy Now | — | Morgan Stanley | Terence Flynn66% | → $11 | Initiates | → Equal-Weight | Get Alert |
| 10/07/2022 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $54 → $53 | Maintains | Buy | Get Alert |
| 07/12/2022 | Buy Now | — | Needham | Gil Blum51% | $38 → $32 | Maintains | Buy | Get Alert |
| 07/11/2022 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $60 → $54 | Maintains | Buy | Get Alert |
| 07/08/2022 | Buy Now | — | Baird | Joel Beatty69% | $41 → $32 | Maintains | Outperform | Get Alert |
| 07/08/2022 | Buy Now | — | JP Morgan | Eric Joseph47% | $46 → $37 | Maintains | Overweight | Get Alert |
| 05/31/2022 | Buy Now | — | Wells Fargo | Derek Archila58% | → $25 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/27/2022 | Buy Now | — | Needham | Gil Blum51% | $48 → $38 | Maintains | Buy | Get Alert |
| 04/18/2022 | Buy Now | — | RBC Capital | Gregory Renza48% | $42 → $39 | Maintains | Outperform | Get Alert |
| 04/14/2022 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $62 → $60 | Maintains | Buy | Get Alert |
| 04/11/2022 | Buy Now | — | Wells Fargo | Derek Archila58% | $28 → $25 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Nurix Therapeutics (NRIX) stock?
The latest price target for Nurix Therapeutics (NASDAQ:NRIX) was reported by Leerink Partners on March 17, 2025. The analyst firm set a price target for $16.00 expecting NRIX to rise to within 12 months (a possible 27.49% upside). 41 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nurix Therapeutics (NRIX)?
The latest analyst rating for Nurix Therapeutics (NASDAQ:NRIX) was provided by Leerink Partners, and Nurix Therapeutics initiated their market perform rating.
When was the last upgrade for Nurix Therapeutics (NRIX)?
The last upgrade for Nurix Therapeutics Inc happened on May 31, 2022 when Wells Fargo raised their price target to $25. Wells Fargo previously had an equal-weight for Nurix Therapeutics Inc.
When was the last downgrade for Nurix Therapeutics (NRIX)?
There is no last downgrade for Nurix Therapeutics.
When is the next analyst rating going to be posted or updated for Nurix Therapeutics (NRIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nurix Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nurix Therapeutics was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.
Is the Analyst Rating Nurix Therapeutics (NRIX) correct?
While ratings are subjective and will change, the latest Nurix Therapeutics (NRIX) rating was a initiated with a price target of $0.00 to $16.00. The current price Nurix Therapeutics (NRIX) is trading at is $12.55, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.